Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Early life exposure to antibiotics and acid suppressants increases obesity risk

A study of almost 300,000 children revealed that exposure to a combination of antibiotics and acid suppressants in the first two years of life is associated with a 42% increased risk of childhood obesity.

Exposure to antibiotics and acid suppressants in the first two years of life is associated with an increased risk of obesity later in childhood, particularly if prescribed in combination, study results show[1].

The study included data on 241,502 children prescribed an antibiotic, 39,488 children prescribed an H2 receptor antagonist (H2RA) and 11,089 children prescribed a proton pump inhibitor (PPI). Obesity was first diagnosed at a median age of three years and was defined as the first body mass index measurement from a clinical encounter that was greater than or equal to the 95th percentile for age and sex. 

The researchers found that antibiotic exposure was associated with a 26% increased risk of obesity (unadjusted hazard ratio [HR] 1.26; 95% confidence interval [CI] 1.23–1.28), while acid suppressants were weakly associated with a higher risk (unadjusted HR 1.04 and 1.03 for PPIs and H2RAs, respectively).

But, combinations of exposure to the three medicine types were associated with increasing risk of obesity, with those exposed to all three having a 42% increased risk (adjusted HR 1.42; 95% CI 1.33–1.51).

The authors suggested this association could be driven by the effects of these medicines on gut microbiota. They said the findings underscore the importance of appropriate stewardship with these medicines.

“These findings should give pause to providers who may renew anti-acid medication prescriptions without proven clinical benefit or prescribe an antibiotic course in the absence of a true medical indication,” the team wrote in Gut (30 October 2018).

Citation: Clinical Pharmacist DOI: 10.1211/CP.2018.20205890

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.